StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a report issued on Friday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 3.0 %
NASDAQ:TTNP opened at $5.73 on Friday. Titan Pharmaceuticals has a 52 week low of $4.24 and a 52 week high of $14.80. The business’s 50 day moving average is $5.81 and its two-hundred day moving average is $6.58.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last issued its quarterly earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- How to Use the MarketBeat Stock Screener
- GE Vernova’s Rally Could Continue as Wind Business Gains Ground
- How Can Investors Benefit From After-Hours Trading
- DraftKings vs. DoubleDown: Growth in the Online Gambling Boom
- Overbought Stocks Explained: Should You Trade Them?
- Join UiPath’s AI Surge and Catch the Coming Stock Price Reversal
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
